D. Carmier

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Arnaud Scherpereel, Julien Mazières, Laurent Greillier et al. · The Lancet Oncology · 2019 · 451 citations · Full text

Ifct-1501 Maps2, Immune Checkpoint Inhibitor, Pleural Disease +5

[Interstitial lung disease in connective tissue disorders].

D. Carmier, Élisabeth Diot, Laurent Guilleminault et al. · PubMed · 2014 · 239 citations

Asthma, Rheumatology, Translational Medicine +15

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette et al. · Journal of Thoracic Oncology · 2019 · 181 citations · Full text

Medicine, Pharmacology, Pathology +8

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 123 citations · Full text

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Guillaume Herbreteau, Alexandra Langlais, Laurent Greillier et al. · Journal of Clinical Medicine · 2020 · 45 citations · Full text